Pharmamark a new on-tablet laser inscription technique to be used on film coated tablets
Indian Court Ruling will give advantage to domestic drug makers who don’t have to worry about bigger foreign rivals expanding in India and poaching their best scientists
Pharmaceutical companies in United Kingdom are turning increasingly to home delivery of medicines as a way to boost profits by cutting out wholesalers and pharmacists.
Dr Ramesh Mashelkar, formerly the Director General of the Council of Scientific and Industrial Research (CSIR) in India, has assumed office as the first president of Global Research Alliance (GDR),
Dr M Venkateswarulu, Drugs Controller General of India (DCGI), (in-charge) has got six months extension on the recommendation from the Indian Health Ministry.
Researchers have unraveled the structure of a key enzyme that can trigger allergies and asthma, giving hopes for more effective therapies
Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.
SMEs are in need of financial assistance. The institutions like Small Industries Development Bank of India (SIDBI), State level Finance Corporations (SFC), National Small Industry Corporations (NSIC) etc provide long, medium and short term loans…
Small and medium enterprises (SMEs) in the pharmaceutical industry have of late been earning quick and huge revenues from Contract Research and Manufacturing Services (CRAMS). This growing area has tremendous potential not only in domestic market but also in the globally. Most of the SMEs will not only survive but also thrive as the Indian crams market is estimated to touch the $900 million – mark by 2010
The Central Government has exempted SSI drug manufacturing units registered with any Central Technical Authority or State Directorate of Industries from fixation of retail price of Scheduled formulation…Policy to protect SSI Units
The following Act of Parliament received the assent of the President on the 16th June, 2006, and is hereby published for general information :SME DEVELOPMENT ACT, 2006
Leading Indian pharmaceutical majors are altering their business strategies by placing greater focus on R&D and the discovery of new chemical entities.
The Union Budget for 2007-08 (April/March) has provided wide-ranging tax benefits to research and development companies of the pharmaceutical and biotechnology sectors. These include extension of weighted deduction benefit on R&D expenditure. The companies that could benefit from these concessions include Ranbaxy, Dr. Reddy’s, Biocon, Sun Pharma, Zydus Cadila, Wockhardt etc.
Indian Pharmaceutical industry is highly fragmented with more than 20,000 registered units. The leading top 300 companies control 70% of the market with market leaders holding nearly 7% of the market Share. More than 6000 small units form core of the industry.
Ranbaxy Laboratories, Dr.Reddy’s Laboratories and Cipla have topped the list of 20 Indian pharmaceutical companies in terms of Revenue from net sales in 2006-07.
The Indian pharmaceutical industry, which has made phenomenal progress in recent years, is expected to maintain an annual average growth of about 15-20 percent in the period between 2005 and 2010. Pharmaceutical exports touched $4.7 billion in 2005-06. According to the Economic Survey 2006-07, the value of pharmaceutical output had grown to $12.4 billion in 2005-06 from a mere $1.1 billion in 1990.